Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Simona Palladino, Valentina Perrone, Elisa Giacomini, Diego Sangiorgi, Eleonora Premoli, Diletta Valsecchi, Luca Degli Esposti & Matteo Basilio Suter. (2023) Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-8.
Read now
Read now
Joshua Blume, Luisa Claus, Tamara Isermann, Antje Dickmanns, Lena-Christin Conradi, Ramona Schulz-Heddergott & Matthias Dobbelstein. (2023) CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan. Cell Cycle 22:13, pages 1563-1582.
Read now
Read now
Articles from other publishers (2)
Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumí, Elena Aguirre, Miguel Ángel Seguí, Manuel Atienza, Silvia Díaz-Cerezo, Alberto Molero, José Manuel Cervera & Joaquín Gavilá. (2023) Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS). Clinical and Translational Oncology.
Crossref
Crossref
Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling & Agnes Jager. (2023) Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands. JAMA Network Open 6:2, pages e2256170.
Crossref
Crossref